Nitric oxide: Antidepressant mechanisms and inflammation

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Major depressive disorder (MDD) affects millions globally, with significant societal burden.
• Current MDD treatments primarily target biogenic amines like serotonin and norepinephrine.
• Emerging evidence suggests other biological systems, including nitric oxide (NO), play a role in MDD.

Purpose of the Study:

• To highlight the potential role of nitric oxide (NO) signaling in the pathophysiology and treatment of MDD.
• To review evidence supporting NO's involvement in depression.

Main Methods:

• Review of studies investigating NO levels in MDD patients.
• Analysis of research on NO signaling modulators' effects in MDD models.
• Examination of NO signaling's interaction with inflammatory pathways relevant to MDD.

Main Results:

• Altered NO levels are observed in individuals with major depression.
• Modulators of NO signaling demonstrate antidepressant effects in clinical and animal studies.
• NO signaling pathways are targeted by various antidepressants in depression models.
• NO signaling potentially modulates inflammatory pathways implicated in MDD pathophysiology.

Conclusions:

• Findings support a significant role for NO signaling in MDD.
• NO pathways represent a promising target for developing novel antidepressant therapies.
• Further research into NO signaling could lead to innovative treatments for MDD.